key: cord-0983616-t6ev4hw3
authors: Moreira, Jorge Lucas de Sousa; Barbosa, Sarah Maria de Sousa; Júnior, Jucier Gonçalves
title: Pathophysiology and molecular mechanisms of liver injury in severe forms of COVID-19: an integrative review
date: 2021-07-23
journal: Clin Res Hepatol Gastroenterol
DOI: 10.1016/j.clinre.2021.101752
sha: ad98ff8fc5463187b393a6474b59d4e27a2e14d5
doc_id: 983616
cord_uid: t6ev4hw3

BACKGROUND AND AIMS: SARS-CoV-2 has primary pulmonary impairment, but other organs such as the liver can also be affected. This implies a worsening of patient's prognosis and an increase in morbidity and mortality. The metabolic pathways and molecular factors involved in the genesis of this injury are still unknown. Therefore, we aimed to carry out an integrative review about the pathophysiology and possible molecular mechanisms of liver injury by COVID-19. METHODS: We carried out an integrative literature review in the following databases: PubMed, Scopus, and Embase from December 2020 to March 2021 using the following descriptors: # 1 “COVID-19” (MeSH) AND / OR # 2 “Liver injury” (MeSH) AND / OR # 3 “Pathophysiology” (MesH). RESULTS: The data were extracted and divided into two main themes, for heuristic purposes: “Hepatotropism and SARS-CoV-2”, and “Pathophysiological hypotheses for liver injury associated with SARS-CoV-2”. CONCLUSIONS: The virus seems to promote liver damage through five mechanisms: direct injury, humoral and cellular inflammatory response, hypoxemia caused by a decrease in the effective circulating volume, reinfection through the portal system, and use of drugs in the treatment. The literature also points out that the expression of the angiotensin-converting enzyme II and transmembrane serine protease 2 receptors is expressive in cholangiocyte and is present in hepatocytes, which is a risk factor for the virus to enter these cells. Finally, patients with previous liver disease appear to be more susceptible to liver injury by COVID-19.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the 2019 coronavirus disease (COVID- 19) , infecting more than 120 million people and causing more than 2.6 million deaths worldwide as of March 15, 2021 [1] . Although SARS-CoV-2 is recognized for causing significant lung damage, extrapulmonary manifestations have been reported around the world [2] , including liver damage, both by serum markers and histological evaluation [3] .

According to literature data, the correlation between the virus and liver disfunction reaches more than half of the cases in epidemiological studies, which point to the incidence of liver damage associated with cases of COVID-19 infection that range from 4.8 to 53% [3] [4] [5] . A meta-analysis that evaluated 15,103 patients with COVID-19 showed that 45.6% of those admitted to hospital units demonstrated a decrease in serum albumin levels, 37 .2% showed an increase in aspartate aminotransferase (AST), 26 .6% had an alanine aminotransferase (ALT) increase, and 18 .2% had raised serum bilirubin levels (95% CI, P< 0,01). During the hospitalization process, the highest incidence found was an increase in AST (69.1%) and a lower incidence of hypoalbuminemia (7.9%) [6] .

According to previous studies, the hepatocellular lesion appears to be the result of genetic, environmental, and iatrogenic factors [2, 3] . Hematimetric changes, such as leukopenia, neutropenia, and lymphopenia; epidemiological variables, such as male gender and age; use of hepatotoxic medications, such as hydroxychloroquine and tocilizumab; and previous pathologies such as hepatic steatosis are possible markers of worse prognosis in these patients [4, 7, 8] .

However, despite the global collective effort, the factors associated with liver injury have not been well mapped yet. Therefore, we aimed to conduct an integrative literature review in order to understand the molecular and pathophysiological mechanisms of liver injury by COVID-19.

We carried out an integrative literature review in the following databases:

PubMed, Scopus, and Embase. Papers were selected using the following search strategy: # 1 "COVID-19" (MeSH) AND / OR # 2 "Liver injury" (MeSH) AND / OR # 3 "Pathophysiology" (MesH), which was repeated by three independent researchers.

The sample included: papers published between December 2020 and March 2021; manuscripts that addressed a combination of the terms proposed in the search strategy; and papers that discussed the probable direct or indirect pathophysiological mechanisms related to liver injury induced by SARS-CoV-2.

After selection of papers by titles and abstracts, the researchers started reading the texts. The exclusion criteria were: papers repeated in more than one database; papers with fragile methodology or without methodology.

The data were extracted and divided into three main themes for heuristic purposes: hepatotropism and SARS-CoV-2 and pathophysiological hypotheses for liver injury by SARS-CoV-2. Data were also described as mind maps to facilitate the information visualization (Figures 1 to 3 

Histopathological analyses have identified the expression of angiotensinconverting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) receptors in hepatocytes (low expression) and in cholangiocyte (high expression).

However, in metabolic stress, up-regulation of these receptors was observed in hepatocytes. These receptors are fundamental for the entry of the virus in human cells and, therefore, for viral hepatotropism [2, 3] . Viral tropism for a specific tissue is determined by the availability of viral receptors on the cell surface [9] . The entry of SARS-CoV-2 into human cells is mediated by the viral protein Spike (S), which interacts with the ACE2 and TMPRSS2 receptors [10] (Figure 1 and 2 ). There is an expression of ACE2 receptors in hepatocytes at small amounts. In contrast, the incidence of these receptors in the epithelium of the bile duct proved to be similar to that of alveolar cells in the lung [11] . These data are corroborated by experimental studies and computational informatics, in which it is possible to infer the number of ACE2 and TMPRSS2 receptor populations [12] [13] [14] [15] ( Figure 1 and 2) .

Interestingly, the increase in AST/ALT is greater in patients with COVID-19 compared to gamma-glutamyltransferase (GGT) and alkanine phosphatase (AF). A Chinese study with 156 patients with COVID-19 showed that 41% had AST/ALT elevation [13] [14] [15] . The most severe cases are associated with lower levels of albumin, high levels of circulating B and T lymphocytes, higher levels of protein Spikes (S) in the cytoplasm of hepatocytes and dysfunction of organelles such as mitochondria and endoplasmic reticulum [15] . Three possibilities stand out to explain this phenomenon:

(I) cell dysfunction due to direct aggression to the virus or/and systemic inflammation;

(II) the hepatotoxic potential of the medications used in the treatment for COVID-19more explored in the following sessions; (III) other membrane proteins that have not yet been mapped or co-stimulators that influence the binding between ACE2 and S.

In this context, recent study systematically compared differential cell tropism, viral replication kinetics, and cell damage profiles of SARS-CoV-2 and SARS-CoV. The liver cell line Huh7 was the third most susceptible to SARS-CoV-2 replication (p=0.012), preceded by Calu3 pulmonary cells (p=0.0003) and Caco2 intestinal cells (p=0.0009) [13] . Up to 43% of patients with COVID-19 and 44% of patients with SARS developed liver dysfunction. Patients with COVID-19 who needed intensive care had significantly higher amounts of elevated liver necrosis markers. They presented more than three times the upper limit within the normal range when compared with those who did not need intensive care [14, 15] .

There is also the possibility of alternative pathways to ACE2 receptors for liver infection with SARS-CoV-2 [16] . The liver/lymph node-specific intercellular adhesion molecule-3-grabbing integrin (L-SIGN) receptor is a liver-specific capture receptor for viral infection and immunity [17] . The SARS-CoV glycoprotein can use both ACE2 and L-SIGN in the infection and pathogenesis of the virus [18] . CD147 is another possible receptor for SARS-CoV-2. It is highly expressed in tumor and inflamed tissues, as well as in pathogen-infected cells [19] (Figure 2 ). Some indications cite that its binding to protein S may be a new route of entry for SARS-CoV-2 [20] .

Direct cytopathic effects SARS-CoV-2 promotes intracellular cytotoxic actions directly to hepatocytes ( Figure 1 ), such as destruction of cell membranes and diffuse edema in structures such as rough endoplasmic reticulum and mitochondria. This decreases protein production and compromises hepatocyte ATP biosynthesis [13, 21] . However, due to the large population of receptors, especially ACE2 and TMPRSS2 in the cells of the bile ducts, liver damage may start through the bile duct [22] . Alternatively, it is hypothesized that some hepatocytes regenerated after external insults, such as the viral infection itself or previous liver damage, have an important increase in the expression of ACE2 in their membranes, due to compensatory hyperplasia and, therefore, would be more susceptible to reinfection/destruction [23] .

Preliminary analyses indicate that SARS-CoV-2 induces decreased mitochondrial activity and oxidative stress in the endoplasmic reticulum [24] [25] [26] [27] [28] . At the same time, the virus seems to have the capacity of inducing mitochondrial β-oxidation defects, promoting direct interference in hepatic lipogenesis [24] [25] [26] . Therefore, both can be caused by direct cytopathic effects of the new coronavirus, contributing to steatohepatitis secondary to the virus and deteriorating the hepatic metabolic condition, thus aggravating comorbidities such as non-alcoholic fatty liver disease (NAFLD) [10] .

The target of rapamycin in mammals (mTOR), an intracytoplasmic enzyme that acts on cell growth, maturation, and proliferation, is also an inducer of lipogenesis and a regulator of autophagy [29, 30] . Studies have shown that SARS-CoV-2 restricts autophagy in a manner similar to the mTOR-dependent mechanisms that had already been observed in SARS-CoV and MERS-CoV [31] . In addition, the increase in interleukin-6 (IL-6) promoted by the inflammatory cascade in the virus presence is responsible for activating the mTOR pathway [32] . Hence, direct hepatocyte infection or cytokine storm can stimulate hyperactivation of hepatic mTOR signaling and, therefore, hepatic steatosis in patients affected by COVID-19 [10] .

Effects of cytokine release syndrome and immune response Active replication and virus release by infected cells culminate in the phenomenon of pyroptosis, which is responsible for releasing molecular patterns associated with damage (ATP, nucleic acids). When endothelial cells and alveolar macrophages recognize such cellular products, there is a trigger of proinflammatory cytokines and chemokines, mainly. IL-6, macrophage inflammatory protein 1α (MIP1α), MIP1β and MCP 1 (Figure 3 ).

The release attracts monocytes, macrophages and T cells to the site, increasing inflammation. The accumulation of immune cells and, therefore, proinflammatory cytokines, constitutes the 'cytokine storm' or 'cytokine release syndrome' (CRS) ( Figure   1 and 3) , damaging the pulmonary structure and afflicting in a multisystemic way to the other organs [33] . IL-6 is involved not only in the acute inflammatory response, but also in liver regeneration and metabolic function of the liver. Molecular signaling of IL-6 occurs through signaling, classical cis or trans signaling pathways. In both signals, IL-6 binds to IL-6R forming a complex with the gp130 dimer. In the classic cis path, the dimerization of the complex formed by IL-6R and gp130 activates the JAK-STAT signaling cascade, contributing to CRS. Hepatocytes can be responsive to IL-6, as some express IL-6R [34, 35] (Figure 3 ). In the trans signaling pathway, the molecular cascades described before are activated in cells that do not express IL-6R, thus expanding the cell types affected by the 'cytokine storm' [36] .

In contrast, there is a negative regulation of ACE 2, resulting in the accumulation of angiotensin II (Ang II), in the viral complex endocytosis. Ang II also acts as a proinflammatory cytokine via the AT1R-metalloprotease 17 (ADAM17) axis. ADAM17

can cleave the membrane form of IL-6Ra, thereby generating soluble IL-6R, which binds to IL-6 and subsequently activates STAT signaling. Trans signaling stimulates the production of pro-inflammatory cytokines and chemokines, including IL-6. Therefore, IL-6 can act as an amplifier for CRS activation [23] .

The direct correlation between systemic inflammation and liver injuries, mainly indicated by IL-6, C-reactive protein (CRP) and ferritin, has been reported in the literature [37] . IL-6, ferritin and CRP levels were correlated with a significant increase in AST (p<0.001), in patients hospitalized in and out of the intensive care treatment.

Interestingly, higher levels of CRP were found in patients with liver dysfunction without criteria for intensive care. Despite the limitation of a cross-sectional design of this study, it was proposed that the systemic inflammatory response to infection by SARS-CoV-2 in patients with COVID-19 should serve as an incentive for liver injury [38] .

Changes in body hemodynamics and oxygen supply were also shown to be possible contributors to liver injury [39] (Figure 1 ). Experimental studies suggest that reduced oxygen levels and accumulation of lipids in hepatocytes during hypoxemia secondary to CRS can lead to cell death [40] . Thus, the hypoxia-reperfusion injury contributes to liver failure to the extent that it involves a dynamic process of cell injury, which encompasses a dual system comprised of an ischemic phase and an inflammatory response induced by reperfusion [41] .

The interruption of adequate blood supply triggers a series of cellular metabolic disorders, leading to a subsequent increase in the reactive oxygen species (ROS) and its peroxidation products [42] . Then, there is activation of transcription factors sensitive to oxidation, amplifying the release of several pro-inflammatory factors (IL-1, IL-6, TNFalpha) and promoting immune activation of TCD4+ and TCD8+ lymphocytes and macrophages that produce colony stimulating factors (GM-CSF and IFN gamma) in the liver after reperfusion.

types of non-parenchymal cells, which is a possible generator of hepatocellular lesions [23] . It is understood that in patients with COVID-19 at severe conditions, ischemic hepatitis is an important factor in secondary liver damage. It can be perceived in the laboratory through the marked increase in aminotransferases in the context of respiratory failure, shock, or heart failure [39] .

Pre-existing chronic liver disease as a factor of worse prognosis in patients with COVID-

The effects of pre-existing chronic liver disease (CLD) on the severity of COVID-19 are well documented in the literature as risk factors for more severe forms of COVID-

cirrhosis, alcohol-reports liver disease (ADL) and hepatocellular carcinoma (HCC) were isolated factors associated with high mortality rates in individuals with CDL [43] . Similar findings were found in the study by Hashimi et al (2020) [44] in which CDL was an isolated risk factor for increasing mortality. Including, data survey carried out between March and April 2020 demonstrates higher mortality by COVID-19 in patients with greater Child-Pugh class. The Child-Pugh class C is up to 3 times more likely to have worse outcomes (death) when compared to the Child-Pugh class A [45] . The US cohort carried out in August 2020 also evaluated 2,780 patients with and without liver disease. The patient with CDL presents higher risk of hospitalization and 4.6 relative risk (RR) for death, compared to controls [46] . However, some early studies lacked this well-documented evidence [47] .

Another point to be raised is that in previous studies, CLD is accompanied by other comorbidities such as systemic arterial hypertension, diabetes mellitus, pulmonary disorders, cardiac diseases, drug use such as alcohol and obesity [43] [44] [45] [46] . In this context, subgroup analyzes are essential to understand the real impact of CDL in patients with COVID-19. However, this is the clinical reality of most patients.

Really, in theory, due to the systemic immunocompromise state, patients with CLD may be more susceptible to SARS-CoV-2 infection. Patients that present decompensated cirrhosis and comorbidities, such as diabetes and obesity, may have a more severe and progressive acute liver damage [48] . Considering the association with other pre-existing comorbidities, early isolation, intensive surveillance, and timely diagnosis become essential for these patients [23] .

Liver and gastrointestinal manifestations have appeared more frequently in the severe forms of COVID-19 infections [49] . A recent study found that patients with gastrointestinal symptoms are more likely to have liver damage than those without these symptoms [50] .

Due the various possible clinical scenarios in the context of liver disease, the hypothesis that viruses could enter the portal circulation to reach the liver has proved to be plausible considering that ACE2 is highly expressed on the brush border of small intestine enterocytes. Assuming there is a rapid viral replication in the intestine, Kupffer's liver cells would attempt to eliminate the virus and initiate an inflammatory response, or mediators of inflammatory bowel diseases would enter the portal system and sinusoidal [39] . This statement is corroborated by a meta-analysis developed by "gut-liver axis disruption" would increase antigenic translocation and activate the immune system [52] . This would occur due to factors such as: (I) local endothelial injury leading to the destruction of tight junctions (TJ) by TNF alpha increase [53] ; (II) decrease in native microbiota and increase in opportunistic bacteria (eg.: Rothia spp., Streptococcus spp., Actinomyces spp and Veillonella spp.) in patients with COVID-19 compared to control groups [54] ; (III) alteration of ACE2 expression in enterocytes secondary to dysbiosis [55] ; and (IV) the presence of the "gut-lung axis", in which the inflammatory process of COVID-19 would cause mucosal ischemia and bacterial translocation. While translocation would feed back the inflammatory process [56] . 

Finally, it is noteworthy that the use of drugs for clinical or off-label tests during the COVID-19 pandemic, in addition to self-medication are factors that contribute to liver injury in patients with COVID-19. This type of injury, called drug-induced liver injury (DILI), is an adverse reaction to drugs or other xenobiotics that occurs as a predictable event when an individual is exposed to toxic doses of some compounds or as an unpredictable event with many drugs of common use [57] .

Known hepatotoxic medications have already been used on a large scale, such as antipyretics (acetaminophen), antivirals (remdesivir, lopinavir/ritonavir), antibiotics (macrolides), antimalarials (hydroxychloroquine) and immunomodulators (corticosteroids, tocilizumab).

A hepatotoxic potential has already been confirmed in in vitro/in vivo experiments and in their respective registry studies for most of these drugs (e.g., ritonavir or remdesivir) [10, 58] . In this context, several mechanisms have been proposed for DILI. Five highlight here: (I) increased intracellular oxidative stress due to damage to intracytoplasmic organelles; (II) apoptosis measured by Fas pathways to TNF alpha; (III) neutrophil-mediated and T-Lymphocyte-mediated liver destruction [59] ; (IV) inhibition of the bile salt export pump (BSEP); (V) mitotoxicity and hepatocyte cytolethality [60] ; (V) potential effects of COVID-19 in P450 Cytochrome (CYP-450).

Some theories suggest that COVID-19 by CRS, due to the treatment used (eg.

glucocorticoids or antivirals drugs) and previous use of other medications (eg. such as antihypertensives, statins and oral hypoglycemic agents). This situation would overload CYP-450, compromising protein metabolism and going through direct liver toxicity [61, 62] . Nevertheless, others, with hepatotoxic potential that has not been well recognized yet, seem to have reports in literature, such as tocilizumab [63] , whose hepatic metabolism and interference in the IL-6 pathway related to liver regeneration is the most likely etiology for its hepatotoxic effect [64] .

Importantly, these mechanisms can be agonists in liver destruction in synergism with dysfunction caused by SARS-CoV-2, CRS caused by COVID-19, ischemia due to septic shock and susceptibility caused by membrane receptors (e.g. CD147, L-SING, ACE2, TMPRSS6).

Therefore, the likely pathophysiological mechanisms for SARS-CoV-2 hepatotropism appear to be closely correlated with the susceptibility of the Huh7 lineage hepatocyte and the presence of the membrane proteins CD147 and L-SIGN to the SARS-CoV-2 protein, which amplify viral invasion and cell dysfunction.

Regarding the pathophysiological mechanisms of the hepatocellular injury of SARS-CoV-2, they are mainly related to the direct cytopathic effects of a probable viral invasion; the increase in populations of ACE2 and TMPRSS6 receptors in bile duct cells, leading to bile duct injury as the genesis of liver disease; hyperactivation of intracytoplasmic mTOR signaling; and CRS with high levels of IL-6. In addition, we highlight not only the role of injury caused by reperfusion injury in the context of circulatory system failure that leads to ischemic hepatitis, but also the use of hepatotoxic drugs in the management of hospitalized or non-hospitalized patients.

However, the relationship between gastrointestinal and hepatic symptoms is not a consensus.

Finally, other studies should perform multicenter, observational, and animalbased clinical studies in order to understand and to improve the dynamics of the immune system, the host-parasite process and the inflammatory response in COVID-19, besides to learn how it interferes with liver function.

An interactive web-based dashboard to track COVID-19 in real time

Extrapulmonary manifestations of COVID-19

Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data

Hepatotoxicity, Drug-Induced. Encyclopedia Of Gastroenterology

Liver injury during highly pathogenic human coronavirus infections

Hepatic manifestations and complications of COVID-19: A systematic review and meta-analysis

Incidence, patterns, risk factors, and histopathological findings of liver injury in coronavirus disease 2019 (COVID-19): a scoping review

Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations

Identification of Carbohydrate-Binding Domains in the Attachment Proteins of Type 1 and Type 3 Reoviruses

Pathophysiological mechanisms of liver injury in COVID-19

Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection

SARS-CoV-2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID-19

Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study

Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Specific Asparagine-Linked Glycosylation Sites Are Critical for DC-SIGN-and L-SIGN-Mediated Severe Acute Respiratory Syndrome Coronavirus Entry

CD 209L) is a liver-specific capture receptor for hepatitis C virus

CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus

The Biological Function and Clinical Utilization of CD147 in Human Diseases: A Review of the Current Scientific Literature

CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations

COVID-19: Abnormal liver function tests

COVID-19-associated liver injury: from bedside to bench

Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease

Adaptation of Hepatic Mitochondrial Function in Humans with Non-Alcoholic Fatty Liver Is Lost in Steatohepatitis

UPR Pathways Combine to Prevent Hepatic Steatosis Caused by ER Stress-Mediated Suppression of Transcriptional Master Regulators

-2 induces a unique mitochondrial transcriptome signature

Modulation of the Unfolded Protein Response by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein

mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway

mTOR at the nexus of nutrition, growth, ageing and disease

Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics

Mesenchymal stem cellsderived IL-6 activates AMPK/mTOR signaling to inhibit the proliferation of reactive astrocytes induced by hypoxic-ischemic brain damage

The trinity of COVID-19: immunity, inflammation and intervention

INTERLEUKIN-6: From Basic Science to Medicine-40 Years in Immunology

Targeting Interleukin-6 Signaling in Clinic

IL-6 as a keystone cytokine in health and disease

Systemic inflammation as fuel for acute liver injury in COVID-19

IL-6 pathway in the liver: From physiopathology to therapy

Abnormal Liver Function Tests in Patients With COVID-19 : Relevance and Potential Pathogenesis

Creg in Hepatocytes Ameliorates Liver Ischemia/Reperfusion Injury in a TAK1-Dependent Manner in Mice

Hepatic ischemia and reperfusion injury: Effects on the liver sinusoidal milieu

COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies

Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study

Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: A multicentre United States experience

High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry

Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients with Preexisting Liver Disease in the United States: A Multicenter Research Network Study

Chronic liver disease is not associated with severity or mortality in Coronavirus disease 2019 (COVID-19): a pooled analysis

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

Association of Digestive Symptoms and Hospitalization in Patients With SARS-CoV-2 Infection

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis

Intestinal Barrier Function in Health and Disease-Any Role of SARS-CoV-2? Microoganisms. 8

TNF-α-induced intestinal epithelial cell shedding: Implications for intestinal barrier function

Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza

Gnotobiotic rats reveal that gut microbiota regulates colonic mRNA of Ace2, the receptor for SARS-CoV-2 infectivity

Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients

Drug-induced liver injury

Elucidation of remdesivir cytotoxicity pathways through genome-wide CRISPR-Cas9 screening and transcriptomics

Mechanisms of hepatotoxicity

Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies

Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients

COVID-19: Direct and Indirect Mechanisms of Statins

First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury

National Institute of Diabetes and Digestive and Kidney Diseases